Radcliffe Capital Management’s Translational Development Acquisition Corp TDAC Stock Holding History
Bought
Maintained
Sold
Other funds holding TDAC
Radcliffe Capital Management's TDAC Position: Q3 2026 in Review
Radcliffe Capital Management reduced its Translational Development Acquisition Corp (TDAC) stake by 2.4% in Q3 2026, selling an estimated $69.2K and leaving 265,544 shares worth $2.88M. The position accounts for 0.21% of the portfolio, ranked #177.
Radcliffe Capital Management first reported a position in TDAC in Q2 2025 and has held it in 6 quarters since. The position peaked at $5.35M in Q1 2026. 37 funds tracked by Wall St. Rank hold TDAC as of Q3 2026.
- Radcliffe Capital Management held 265,544 shares of Translational Development Acquisition Corp worth $2.88M as of Q3 2026.
- Radcliffe Capital Management sold 6,396 Translational Development Acquisition Corp shares in Q3 2026, an estimated $69.2K.
- Translational Development Acquisition Corp made up 0.21% of Radcliffe Capital Management's portfolio in Q3 2026, its #177 holding.
- Radcliffe Capital Management first reported a position in Translational Development Acquisition Corp in Q2 2025 and has held it in 6 quarters since.
- Radcliffe Capital Management's Translational Development Acquisition Corp position peaked at $5.35M in Q1 2026.
- 37 funds tracked by Wall St. Rank held Translational Development Acquisition Corp as of Q3 2026.
Based on Radcliffe Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.